Brain metastasis in NSCLC patients, which develops in 15% to 40% of ALK-rearranged patients after first diagnosis [32–34] and in approximately one third after the failure of at least one prior systemic therapy [31], is often considered as the terminal stage of advanced disease. The gene discussed is ALK; the disease is non-small cell lung carcinoma.